Some of the information presented here today contains projections or other forward-looking statements regarding future events or the future financial performance of the Company.

FORWARD-LOOKING STATEMENTS AND DISCLAIMERS

These statements are based on management’s current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company’s annual report on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company’s projections or forward-looking statements. All third-party marks—® and ™—are the property of their respective owners. Certain market and industry data has been obtained from third-party sources, which the Company believes are reliable, but the Company has not independently verified the information provided by third-party sources. Unless otherwise noted, market growth rates used in this presentation are estimates based on Company and third-party industry research. The reported number of patients in Epic's network (250M) and clinicians (2,000+) in Flatiron's network was provided by Epic and Flatiron, respectively.

NON-GAAP FINANCIAL MEASURES

In this presentation, the Company's financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company’s core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company’s business. Definitions of the non-GAAP financial measures and a reconciliation of the GAAP to non-GAAP financial results are provided in the Appendix to this presentation.
Today’s Agenda

Paul J. Diaz
PRESIDENT AND CHIEF EXECUTIVE OFFICER
Well positioned to drive accelerating growth and profitability
Focus on commercial execution and innovation

Marc Leighton
SVP, PRODUCT MANAGEMENT
Addressing large underpenetrated markets with differentiated products and services
Expanding genetic testing in markets affecting millions of lives

Mark Verratti
CHIEF COMMERCIAL OFFICER
Executing to win
Expanding commercial sales and marketing capabilities to increase access to genetic testing and drive growth

Nicole Lambert
CHIEF OPERATING OFFICER
Enhancing core lab capabilities
Supporting growth, productivity, and innovation—Lab of the Future

Dale Muzzey, Ph.D.
CHIEF SCIENTIFIC OFFICER
What’s next
Innovating and elevating our product pipeline

Katie Johansen Taber, Ph.D.
VP, CLINICAL PRODUCT RESEARCH
Closer look at clinical programs and real-world evidence
Robust pipeline of clinical studies

Bryan Riggsbee
CHIEF FINANCIAL OFFICER
Delivering shareholder value
Long-term growth and profitability
Well positioned to drive accelerating growth and profitability
Revealing the power of genetic science – for everyone

Mission
We advance health and well-being for all, empowering every individual by revealing the answers inside each of us.

Vision
As a leader in genetic testing and precision medicine, we provide insights that help people take control of their health and enable healthcare providers to better detect, treat and prevent disease.
Myriad Genetics at-a-glance

**A leader in genetic testing**
Established franchises in hereditary cancer, pharmacogenomics, and prenatal testing

**30+ years of scientific and commercial achievements**
1,000+ scientific publications and counting

**42,000+ active ordering healthcare providers**
**72.5**
net promoter score<sup>1</sup>

**10%+ annual revenue growth for third consecutive quarter<sup>2</sup>**
Commercial execution driving volume growth; price stability

**Market-leading gross margins; healthy balance sheet**

**Innovation in ‘24 and beyond**
Expect to launch multiple differentiated tests in prenatal and oncology through 2026

---

1. As of year end 2022
2. As of second quarter 2023 and excludes contribution from change of revenue estimates
Second quarter operating and financial highlights

<table>
<thead>
<tr>
<th>Double-digit revenue growth despite payor headwinds</th>
<th>Testing volume growth driven across each Business Unit</th>
<th>Positive Trend in Gross Margin and Adj. OpEx</th>
<th>New credit facility adds financial flexibility; on-track to achieve positive adjusted operating cash flow</th>
</tr>
</thead>
<tbody>
<tr>
<td>+10% revenue growth YOY*</td>
<td>+17% volume growth YOY**</td>
<td>Non-GAAP gross margin of 69% increased 130 basis points from Q1 '23.***</td>
<td>Established new $90M asset-based credit facility. Generated $5.9M in adjusted operating cash flow in Q2 '23. Reaffirm adjusted profitability and positive adjusted operating cash flow Q4 '23 targets.</td>
</tr>
<tr>
<td>Third consecutive quarter achieving double-digit revenue growth.*</td>
<td>YOY volume growth by unit: +23% in Pharmacogenomics +14% in Women’s Health** +11% in Oncology</td>
<td>Adjusted operating expenses declined $11.1 million from Q1 '23 to $133.4 million.***</td>
<td></td>
</tr>
</tbody>
</table>

* Excluding contribution from change of revenue estimates of $11.7M in Q2 '22 and an immaterial amount in Q2 '23
** Excluding contributions from the SneakPeek® Early Gender DNA test
***Gross margin and adjusted operating expenses are non-GAAP measures. See Appendix to this presentation for the definitions and a reconciliation to the nearest GAAP measure.
Pillars of long-term growth and profitability

Science and innovation
Top-tier science delivering products that are clinically validated and demonstrate proven utility (quality, access and cost) in real world clinical settings.

Elevated customer engagement and commercial execution
Strong digitally enabled commercial platform.

Technology led operations
Automated, scalable, and cost-effective laboratory operations and technology platform.

Scalable administrative support services
Advanced regulatory, reimbursement, and revenue cycle capabilities.
<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue growth expected to</strong></td>
<td><strong>Goal to generate $1B+ in revenue by 2026</strong></td>
<td></td>
</tr>
<tr>
<td><strong>accelerate 10%+ in ‘24 – ‘26</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Right to win with core</strong></td>
<td>**Enhanced commercial execution generating double-digit volume</td>
<td></td>
</tr>
<tr>
<td><strong>products driving market</strong></td>
<td><strong>growth as adoption rates and competitive position improves</strong></td>
<td></td>
</tr>
<tr>
<td><strong>share gains</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pipeline addresses large</strong></td>
<td>**Robust and differentiated product pipeline opens access to</td>
<td></td>
</tr>
<tr>
<td><strong>growth markets</strong></td>
<td><strong>incremental multi-billion-dollar markets</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Operating leverage,</strong></td>
<td><strong>Strength of business model, technology platform and enhanced</strong></td>
<td></td>
</tr>
<tr>
<td><strong>profitability,</strong></td>
<td>**laboratory capabilities to drive operating leverage,</td>
<td></td>
</tr>
<tr>
<td><strong>and positive cash flow</strong></td>
<td><strong>profitability and cash flow in 2024–2026</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Capital deployment</strong></td>
<td><strong>Disciplined capital deployment; continue to invest in high</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>ROI opportunities within core channels</strong></td>
<td></td>
</tr>
</tbody>
</table>
Diversified portfolio within large, fragmented, actionable markets

<table>
<thead>
<tr>
<th>Actionable Market Opp.¹</th>
<th>Oncology</th>
<th>Women’s Health</th>
<th>PGx</th>
</tr>
</thead>
<tbody>
<tr>
<td>AFFECTED HCT + GERMLINE</td>
<td>AFFECTED HCT + GERMLINE</td>
<td>TUMOR PROFILING³</td>
<td>MRD</td>
</tr>
<tr>
<td>$1.2B</td>
<td>$1.2B</td>
<td>$500M</td>
<td>$20B+</td>
</tr>
<tr>
<td>Market Penetration</td>
<td>Market Penetration</td>
<td>$500M</td>
<td>$20B+</td>
</tr>
<tr>
<td>~65%</td>
<td>~65%</td>
<td>~45%</td>
<td>&lt;5%</td>
</tr>
<tr>
<td>Myriad Products</td>
<td>Myriad Products</td>
<td>MyRisk BRAC CDx</td>
<td>Precise Tumor Precise Liquid (pipeline)</td>
</tr>
</tbody>
</table>

|$30B | <40% | <20% | Myriad holds Top 3 position in 6 out of 7 active product categories |

1: Actionable market indicated against cancers of commercial focus
2: In ovarian, breast, prostate, pancreatic cancers only
3: Reflective of IHC partnership
Data as of 2022 from third party global consulting firm and internal estimates
Marc Leighton
SVP, PRODUCT MANAGEMENT

Addressing large underpenetrated markets with differentiated products and services
Improved product management strategy

Enterprise alignment to deliver on product strategy and help deliver sustainable growth

- Data-driven, user-centric, and research-oriented... *Informs* roadmap strategy
- Relentless pursuit of improving experiences... *Ease of use critical*
- Set and communicate the product vision... *Align the organization to a shared strategy*
- Invest for customer value creation and Myriad sustainability... *Balance innovation with scalability*

Enable our product vision through intentional organizational design
3 focus areas: Women's Health, Oncology, and Pharmacogenomics

### Women's Health
A leader in health and wellness with differentiated genetic insights for women of all ancestries, assessing cancer risk and offering prenatal solutions.

**Business**

<table>
<thead>
<tr>
<th>Actionable Market Size*</th>
<th>Target Customer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$5 Billion</td>
<td>OB/GYN, Maternal Fetal Medicine, Primary Care, Genetic Counselor</td>
</tr>
</tbody>
</table>

**Products**
- MyRisk™: Hereditary Cancer Test
- FirstGene™: Comprehensive Prenatal Screen
- Foresight™: Carrier Screen
- SneakPeek™

2024E Launch

**Market Size**
- $5 Billion

*Source: Based upon company and third-party estimates and industry research

### Oncology
Clarifying cancer treatment with genetic and genomic insights and companion diagnostic tests that are designed to work with corresponding drugs and treatments.

**Business**

| $23 Billion | Oncologist, Surgeon, Urologist, Genetic Counselor |

**Products**
- MyRisk™: Hereditary Cancer Test
- Prolaris™: Prostate Cancer Prognostic Test
- EndoPredict™: Breast Cancer Prognostic Test
- Precise™ Liquid: Molecular Profile Test
- Precise™ Tumor: Molecular Profile Test
- GeneSight™: Mental Health Medication Test

**Target Customer**
- Psychiatrist
- Primary Care
- Nurse Practitioner/Physician Assistant

### Pharmacogenomics
Using genetic insights to help physicians understand how genetic alterations impact patient response to antidepressants and other drugs.

**Business**

| $5 Billion | Genesight™: Mental Health Medication Test |

**Products**
- MyChoice™ CDx: Myriad IRRD Companion Diagnostic Test
- BRACAnalysis CDx™: Germline Companion Diagnostic Test

**Target Customer**
- Genetic Counselor

©2023 Myriad Genetics, Inc. All rights reserved. myriad.com
MyRisk helps identify patients at risk of hereditary cancer

A hereditary test that evaluates patient risk for **11** cancer indications based on **48** clinically significant genes and recommended by the **National Comprehensive Cancer Network (NCCN)** to assess BRCA mutations and eligibility for select treatment protocols.

- **MyRisk® hereditary cancer panel**
- **Clinical and cancer history analysis**
- **RiskScore for breast cancer**

**More than 50%** of unaffected patients tested with MyRisk® with RiskScore® will qualify for a change to their medical management.

*Source: Myriad Internal Data based on OBGYN and Primary Care Settings, 2022

**Source: Myriad internal data based on MyRisk tests reported between 9/1/2021 and 02/01/2023 ordered for unaffected patients by OBGYN & Primary Care healthcare providers.*
MyRisk addresses the needs of large and growing markets

**Unaffected Market – Hereditary Screening**
- Actionable market size (US only): $3B
- Market penetration: 15%
- Market growth: High single digits
- MYGN market share: 30% - 35%

**Affected Market – Germline Screening**
- Actionable market size (US only): $1.2B
- Market penetration: 65%
- Market growth: Mid single digits
- MYGN market share: ~20%

**TOTAL U.S. POPULATION**
- ~332M

**TOTAL U.S. POPULATION WHO WOULD QUALIFY FOR HCT**
- ~50M*

**TOTAL NUMBER OF WOMEN WHO QUALIFY FOR HCT**
- ~25M

**WOMEN WHO QUALIFY FOR HCT AND ARE ACTIVELY INVOLVED IN THEIR HEALTHCARE**
- ~13M

**TOTAL NUMBER OF WOMEN WHO ARE NEWLY ELIGIBLE FOR HCT IN THE PAST YEAR**
- ~800K

**TOTAL NEWLY DX PATIENTS ELIGIBLE TO RECEIVE GERMLINE SCREENING ANNUALLY***
- ~860K

**PATIENTS RECEIVING GERMLINE TESTING ANNUALLY**
- ~550K

*Data as of 2022, source: Third party global consulting firm
*In cancers of focus
All numbers shown are 2022 estimates
Significant opportunity to accelerate MyRisk growth across Women’s Health, Imaging, Oncology and Urology

Roadmap highlights

2023-2024  MyRisk patient portal
RискScore Tyre-Cuzick update
MyRisk Medical Management Tool Enhancements
RiskScore studies
Breast Cancer Risk Assessment Program

2025  Panel Expansion | WES (whole exome sequencing)
BRAC CDx to NGS

Hereditary cancer test volume

Figures in thousands

Roadmap highlights

<table>
<thead>
<tr>
<th>Year</th>
<th>YOY Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q3 ’22</td>
<td>+4%</td>
</tr>
<tr>
<td>Q4 ’22</td>
<td>+19%</td>
</tr>
<tr>
<td>Q1 ’23</td>
<td>+28%</td>
</tr>
<tr>
<td>Q2 ’23</td>
<td>+20%</td>
</tr>
</tbody>
</table>

+16% LTM Volume Growth (YOY)
GeneSight is the market-leading PGx test

GeneSight helps physicians understand how patients will respond to medications used to treat depression, anxiety, ADHD, and other psychiatric conditions.

Ordered by tens of thousands of clinicians to inform medication selection and dosing

Measures multiple genomic variants for each individual to categorize medications and provide clinical considerations

Market leading psychiatric PGx test and the only test backed by seven clinical studies published in peer-reviewed journals

Helps physicians and patients avoid multiple medication trials by informing which medications may require dose adjustments, be less likely to work, or have increased risk of side effects.

2 Million + people have taken the GeneSight test

7 Clinical Studies published in peer reviewed journals, including independent randomized controlled trial in JAMA
## Strong commercial execution driving significant volume growth, last twelve months

### Roadmap highlights

**2023-2024**
- Psych 4.2
  - Indication Expansion
  - Health Economic Outcome Research (HEOR) study

**2025**
- Postpartum Clin Dev Protocol & Study

<table>
<thead>
<tr>
<th>Actionable market size (US only)*</th>
<th>Market penetration*</th>
<th>Market growth*</th>
<th>MYGN market share*</th>
</tr>
</thead>
<tbody>
<tr>
<td>~$5B</td>
<td>15%</td>
<td>Mid teens</td>
<td>55-60%</td>
</tr>
</tbody>
</table>

### GeneSight test volume

**Figures in thousands**

<table>
<thead>
<tr>
<th>Quarter</th>
<th>YOY Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q3 ’22</td>
<td>+34%</td>
</tr>
<tr>
<td>Q4 ’22</td>
<td>+22%</td>
</tr>
<tr>
<td>Q1 ’23</td>
<td>+31%</td>
</tr>
<tr>
<td>Q2 ’23</td>
<td>+23%</td>
</tr>
</tbody>
</table>

*Data as of 2022, source: Third party global consulting firm and internal estimates

This study used data from the Optum Labs Data Warehouse, composed of de-identified administrative claims data for both commercially insured and Medicare Advantage enrollees. The claims data were linked on a de-identified basis with PGx test results.
In localized prostate cancer, Prolaris® is a market leading biomarker test to help determine optimal treatment planning.

Prolaris utilizes **two validated thresholds** to identify men that are safe for active surveillance, candidates for a single type of therapy, and those who would benefit from **multiple therapeutic options**.

---

**Active surveillance**
Men safe for active surveillance

**Single-modal treatment**
- Men not safe for active surveillance
- → candidates for single-modal therapy

**Multi-modal treatment**
- Men not safe for single-modal therapy
- → candidates for multi-modal treatment

---

**LOWER PROLARIS SCORE**  
**ACTIVE SURVEILLANCE**

**HIGHER PROLARIS SCORE**  
**MULTI-MODAL TREATMENT**

---

**RESEARCH VALIDATION**
In a head-to-head study*, Prolaris identified **>86% of low-risk** patients as candidates for active surveillance aligns with NCCN guidelines.

---

Strong runway for Prolaris with an opportunity to capture more market share with compelling updates

Roadmap highlights

**2023-2024**
- ARR (Absolute Risk Reduction) report
- Node Guidance report update
- Pathology AI
- Publish 3-yr Metastasis study

**2025**
- 15-20 yr. DSM report update
- Prolaris Post-RP launch

<table>
<thead>
<tr>
<th>Actionable market size (US only)*</th>
<th>Market penetration*</th>
<th>Market growth*</th>
<th>MYGN market share*</th>
</tr>
</thead>
<tbody>
<tr>
<td>~$600M</td>
<td>35%</td>
<td>Low teens</td>
<td>~40%</td>
</tr>
</tbody>
</table>

**Prolaris test volume**

Figures in thousands

<table>
<thead>
<tr>
<th>Quarter</th>
<th>LTM Volume Growth (YOY)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q3 '22</td>
<td>+3%</td>
</tr>
<tr>
<td>Q4 '22</td>
<td>+26%</td>
</tr>
<tr>
<td>Q1 '23</td>
<td>+21%</td>
</tr>
<tr>
<td>Q2 '23</td>
<td>+13%</td>
</tr>
</tbody>
</table>

*Data as of 2022, source: Third party global consulting firm
Comprehensive prenatal care with differentiated products and reliable technology

**Prequel®**

Prenatal Screen

Shown to deliver accurate answers to patients regardless of age, ancestry, or body mass index—the Prequel Prenatal Screen with AMPLIFY™ helps determine a pregnancy’s risk for a variety of chromosomal conditions.

- AMPLIFY fetal fraction amplification delivers first-time accurate results to >99.9% of patients at 10 weeks.*
- Industry-low screening failure rate** reduces the chance of repeat screens or unnecessary, invasive diagnostics such as amniocentesis.

**Foresight®**

Carrier Screen

Foresight identifies couples at risk of passing down serious, inherited conditions to their children to guide informed planning, preparation and care.

- Highest published at-risk couple detection rate for serious conditions (1 in 22 couples)***
- >99% detection rate for the vast majority of genes in couples across all ancestries

---


A market that continues to grow with potential tailwinds from guideline expansion

<table>
<thead>
<tr>
<th></th>
<th>Prequel</th>
<th>Foresight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actionable market size (US only)*</td>
<td>~$1.3B</td>
<td>~$950M</td>
</tr>
<tr>
<td>Market penetration*</td>
<td>45-55%</td>
<td>40-50%</td>
</tr>
<tr>
<td>Market growth*</td>
<td>Low single digits</td>
<td>Low single digits</td>
</tr>
<tr>
<td>MYGN market share*</td>
<td>Low-to-mid teens</td>
<td>Mid teens</td>
</tr>
</tbody>
</table>

*Data as of 2022, source: Third party global consulting firm

**Roadmap highlights**

- 2023-2024: Foresight on NovaSeq
  - FirstGene Launch
  - Various Prequel studies
  - Foresight Panel Expansion

**Prenatal test volume**

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Figures in thousands</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q3 '22</td>
<td>80</td>
</tr>
<tr>
<td>Q4 '22</td>
<td>85</td>
</tr>
<tr>
<td>Q1 '23</td>
<td>90</td>
</tr>
<tr>
<td>Q2 '23</td>
<td>100</td>
</tr>
</tbody>
</table>

**YOY Growth**

- Q3 '22: +0%
- Q4 '22: (1%)
- Q1 '23: +12%
- Q2 '23: +12%

**LTM Volume Growth (YOY): +6%**
MyChoice CDx is the only FDA-approved, ASCO-endorsed test for HRD in ovarian cancer

Actionable market size (US only)*

~$300M

Market penetration*

<10%

Mid teens

Roadmap highlights

Breast and Prostate indication expansion (2025 – 2026)

HRD+

25%

1 in 2 patients with ovarian cancer are HRD+

Of ovarian cancer patients who are HRD+

1 in 4 HRD+ patients have a BRCA1/2 mutation

15% Somatic

10% Germline

34% more tumors than other testing methods alone

*Data as of 2022, source: Third party global consulting firm, includes indications for Breast, Ovarian, Pancreatic, Prostate
# Myriad Genetics roadmap snapshot

<table>
<thead>
<tr>
<th></th>
<th>2023</th>
<th>2024</th>
<th>2025</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MyRisk</strong></td>
<td>Q1: Foresight panel expansion</td>
<td>Q2: Psych 4.2</td>
<td>Q3: Expand indications</td>
</tr>
<tr>
<td><strong>BRACAnalysis CDx</strong></td>
<td>Q1: Uplift to NGS (Next Generation Sequencing)</td>
<td>Q2: Pathology AI (discovery)</td>
<td>Q3: 3-year Mets Study</td>
</tr>
<tr>
<td><strong>Prolaris</strong></td>
<td>Q1: ARR</td>
<td>Q2: 3-year Mets Study</td>
<td>Q3: Prolaris Post RP</td>
</tr>
<tr>
<td><strong>GeneSight</strong></td>
<td>Q1: MyRisk patient portal</td>
<td>Q2: MyRisk Panel expansion</td>
<td>Q3: Expand indications</td>
</tr>
<tr>
<td><strong>Foresight</strong></td>
<td>Q1: Foresight panel expansion</td>
<td>Q2: Psych 4.2</td>
<td>Q3: Expand indications</td>
</tr>
<tr>
<td><strong>Prequel</strong></td>
<td>Q1: Portal updates, new sequencing</td>
<td>Q2: Portal updates, new sequencing</td>
<td>Q3: Portal enhancements</td>
</tr>
<tr>
<td><strong>FirstGene</strong></td>
<td>Q1: Validation</td>
<td>Q2: Study</td>
<td>Q3: Full Launch</td>
</tr>
<tr>
<td><strong>MyChoice CDx</strong></td>
<td>Q1: Indication Expansion</td>
<td>Q2: Indication Expansion</td>
<td>Q3: Indication Expansion</td>
</tr>
<tr>
<td><strong>Precise Tumor</strong></td>
<td>Q1: Portal enhancements</td>
<td>Q2: Portal enhancements</td>
<td>Q3: Portal enhancements</td>
</tr>
<tr>
<td><strong>Precise Liquid</strong></td>
<td>Q1: Launch</td>
<td>Q2: Launch</td>
<td>Q3: Launch</td>
</tr>
<tr>
<td><strong>Precise MRD</strong></td>
<td>Q1: Pharma Availability</td>
<td>Q2: Pharma Availability</td>
<td>Q3: Pharma Availability</td>
</tr>
<tr>
<td><strong>Whole Exome</strong></td>
<td>Q1: RUO (Research Only)</td>
<td>Q2: RUO (Research Only)</td>
<td>Q3: RUO (Research Only)</td>
</tr>
</tbody>
</table>
Mark Verratti
CHIEF COMMERCIAL OFFICER

Executing to win
30 years and counting:
A commitment to uncovering breast cancer risk

A decade of providing patients with hereditary cancer risk
10 years since the launch of MyRisk

Comprehensive risk assessment to provide 5-year and lifetime cancer risk
Density + Risk Model + Genetics to provide 5-year Breast Cancer risk and lifetime hereditary risk of 11 different cancers

Impactful short and long-term medical management
More than 50% of all patients who take a MyRisk test get a medical management change with assistance of counseling services provided by 50+ live genetic counselors
Building hereditary cancer testing awareness among consumers

Cancer is rising in young people. This little-known syndrome may be one reason why

Having Lynch syndrome makes it more likely to be diagnosed at a young age with several different types of cancer. Singleton discovered he had Lynch syndrome after undergoing a test from Myriad Genetics. Suddenly, the premature death of his relatives made sense.

myriad.com
Our transformation journey takes us on a course of sustainable growth and profitability

2021-22
RESET THE BASE

Sales
Commercial focus primarily through sales channel

Marketing
Growing our in-house marketing functionality across all parts of the business

Enablement
Accelerating the existing foundation with high quality data and technology stack to deliver on our growth

2023
IMPROVE FOUNDATION

Data
Becoming a data-driven organization that can orchestrate customized experiences through data

Insights
Build on a growth-driven model that moves past foundational strengths to unlock new opportunities through insights and customer experience focus

2024-26
UNLOCK NEW GROWTH

Enablement

Marketing

Sales

©2023 Myriad Genetics, Inc. All rights reserved. myriad.com
A strong scalable commercial team – unified in a singular goal

Our commitment and dedication to patients and the providers that treat them come from a 685 person team*

**COMMERCIAL TEAM MEMBERS**

- 59 Enterprise

**ENTERPRISE COMMERCIAL STRATEGY**
- Product management
- Market intelligence
- Sales enablement
- Customer targeting

**ENTERPRISE EXECUTION**
- Public relations
- Digital marketing
- Brand
- Measurement & reporting

**COMMERCIAL BUSINESS UNIT**
- Field sales
- Internal sales
- Marketing
- Medical

**265**
- Women's Health

**180**
- Oncology

**181**
- Pharmacogenomics

*as of August 2023
Operations and commercial enablement bring about efficiency and analytics to help the organization scale to meet demand

- **96%** Of sales team using sales enablement tools
- **77%** Of our salesforce has more than 2 years of service
- **110%** Salesforce 1H 2023 Quota Achievement

- An always-on training model to offer continuous education and training for the sales force in an ever-changing, dynamic market
- Customer segmentation through data analytics platform to drive efficient, actionable growth in the field

**Marketing**
Telling a vibrant story of how we deliver value with authenticity across channels

**Insights**
Identifying opportunities through a constant focus on our customers, patients and their needs

**Operations & Enablement**
Creating the right operating model for sales with a solid foundation of technology-enabled infrastructure

**Product Management**
Using customer insights to develop and enhance our product portfolio
Commercial strategy and priorities

- Growth driven by strength of the complete portfolio
- Exploring adjacent channels to meet the patient and provider where they are
- Accelerating the use of data-driven insights for targeted growth
- Building a sustainable and profitable business across the portfolio with clinically-minded innovation

Myriad Commercial

- **Accelerating integrations**
  - Creating a friction-free experience for providers & patients to retain customers and limit churn

- **Driving depth in account**
  - Seeing wins with driving double and triple-plays with accounts, proving the value of our portfolio of products at each call point

- **Large account focus**
  - A dedicated National Accounts team focused on large accounts

- **Channel Expansion**
  - Entering new channels to meet patients and providers where they are, with products that deliver value
EMR integration streamlines workflows, rapidly expanding test volume

Number of incremental new provider sites integrated with EMR

- **2022**: 511 new sites
- **2023**: 509* new sites
- **2024**: 1,850+ new sites

* Year-to-date as of June 30, 2023
** Measured from average integration 90 days pre-integration to 90 days post-integration.

+20% in MyRisk and Prenatal volume lift in integrated sites**

Accelerating integrations
Key EMR partnerships will enable high-volume testing across the portfolio in large health systems in Women’s Health and Oncology

- **Speed**
  - Turnkey integrations reducing time-to-connection from months to weeks

- **Reimbursement**
  - Bi-directional data exchange reduces exceptions and automates workflows

- **Comprehensive patient care**
  - Seamlessly integrates genetics insights for tailored, personalized care

**Accelerator for Women’s Health**
- 250 million patients in the network
  - Turnkey integration with Epic’s Aura network
  - MyRisk, Prenatal, Genesight available now
  - Full-scale ramp expected in Q4 ‘23

**Oncology focus**
- 2,000+ clinicians nationwide
  - Full suite of oncology products
  - Detailed variant data
  - Expect to launch in 2024
Automated end-to-end workflow to enable frictionless testing at scale for large health systems and physician groups

Patient In-take & Counseling
- Myriad AI-enhanced consumer chatbot engage, educate
- MyGeneHistory streamlines patient intake
- Patient Education Genetic Counseling value of testing
- Myriad Cost Estimator determine patient out-of-pocket costs

Laboratory Testing & Resulting
- Provider Portal Ordering small/medium-sized practices
- Laboratory Genetic Testing
- Provider Portal Resulting physician access to genetic test results
- EMR Ordering larger healthcare systems
- EMR Resulting larger healthcare systems

Patient Care
- Clinical Care/Management Support
- Tyrer Cusik and MyRisk Management breast cancer risks and care recommendations
- Patient Portal patient access to genetic test results

Large account focus
The imaging channel helps Myriad unlock Hereditary Cancer Testing market share from patients who fall through traditional channels

American College of Radiology and Society of Breast Imaging have called for all women 30 years of age and above to have their risk assessment completed.

New FDA “dense breast” reporting requirement going into effect in September 2024

3. Myriad Internal Data (MMT For Unaffected Patient Population in the WH Space)
Entering the consumer-initiated testing segment with growing brand awareness

Predicts babies’ fetal sex as early as 6 weeks of pregnancy with 99% accuracy

>970,000 tests to date (across all channels)

Now available in 3,450 stores

78% of US population lives within 5 miles of Walgreen’s store

10M daily customers in its stores and online

Top retailer for home pregnancy tests

Meeting patients where they are with a comprehensive portfolio
Enhancing core lab capabilities
Healthcare providers (HCPs) with a better perception of Myriad Genetics - reflecting recent developments in accessibility, transparency and experience

Change in opinion about Myriad Genetics among HCPs compared to previous year

- **More Positive Opinion**: +29%
- **More Negative Opinion**: -1%

**SOURCE:** Brand Equity Research 2023, Q14 (N1 in May/Dec 2022): Still thinking about these companies, how has your opinion of each company changed over the past year?

**Base:** Respondents aware of and asked about each brand: Myriad (283)

Reasons why HCP’s opinion of Myriad Genetics has improved over the past year

- **Improved customer support**
  - “They are innovative, easy to communicate with, and responsive to me.”
  - “Customer support has improved over the past year.”
- **Expanded test profiles**
  - “They have a variety of tests that cover not only Women’s Health, but diseases specific to Primary Care.”
  - “They’re expanding their testing options and sharing their data.”
- **Quicker turnaround**
  - “Quicker to provide results and more comprehensive services over the past 2-3 years.”
- **Data transparency**
  - “Being more transparent with their data.”
  - “They’ve offered to make more of their data available to the public.”

More Positive Opinion | +29%
More Negative Opinion | -1%

Aug 2023
# Operational highlights fueling our growth

## Team Engagement

<table>
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Of our team rate Myriad as a “Great Place To Work”</td>
<td>86%</td>
</tr>
<tr>
<td>Employee turnover, approximately half of what it was in 2021</td>
<td>9.6%</td>
</tr>
</tbody>
</table>

## Market Perception

<table>
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net Promoter Score among current Myriad providers ordering across our testing portfolio</td>
<td>67-73%</td>
</tr>
<tr>
<td>Favorable consideration among providers aware of our efforts to share data with ClinVar*</td>
<td>+1300 bps</td>
</tr>
</tbody>
</table>

## Efficiency & Speed

<table>
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rapid turn-around times critical for patients making time-sensitive care decisions**</td>
<td>5.5 days</td>
</tr>
<tr>
<td>YOY reduction in COGS per test scaling with growth, quality and regulatory requirements***</td>
<td>17%</td>
</tr>
<tr>
<td>YOY sales productivity increase with structural optimization, automation and accelerating marketing demand</td>
<td>+14%</td>
</tr>
</tbody>
</table>

## Revenue Cycle

<table>
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increase in collections from 2021 – mid-2023 with fully automated revenue cycle platform</td>
<td>+$40M</td>
</tr>
<tr>
<td>Increase in prior authorization team productivity to scale with sustained high-volume growth</td>
<td>+55%</td>
</tr>
</tbody>
</table>

---

* SOURCE: 2022 survey conducted by Edelman HCP ETM Pulse 2022. Next time you need to recommend testing to a patient, how likely are you to recommend testing from the following company(s) assuming they provide the type of testing your patient needs, and you have the opportunity to choose? December 2022. Base: HCPs who were not aware of the Clinvar Announcement (n=65) / HCPs who were aware of the Clinvar Announcement (n=114) ** as of July 31, 2023 *** Excluding contribution from SneakPeak Early Gender DNA test
End-to-end technology transformation

**Patient & Provider Engagement**
- myGeneHistory
- Myriad.com overhaul
- Intuitive patient and provider portals

**Test Ordering & Order Management**
- Cost estimation and direct pay options for patients
- EMR integration for large accounts
- Ordering portals for smaller clinics

**Laboratory Processing**
- Next-gen sequencing platforms
- Advanced “lights out” robotic automation
- Automated variant curation pipeline

**Results Delivery**
- Personalized, graphical patient report
- Medical Management Tool for actionable results
- Bi-directional EMR w/ variant data

**Reimbursement**
- Automated revenue cycle management
- Advanced analytics platform

$50M+ Investment
Improving customer engagement, reduce friction, and enhance speed and efficiency
$80M investment made over last two years in upgrading and automating labs, tech platforms and test processes

**Assay Enhancement**
- New features for current product

**Real Estate**
- Modernize & streamline real estate portfolio

**Automation**
- Automated backbone for lab operations

**Innovation**
- New differentiated product offerings

**Advanced Sequencing**
- MyChoice
- Foresight
- Prequel

**Migrate to Whole Exome**
- MyRisk

**Build world-class labs**
- New S. San Francisco innovation center
- New Salt Lake City lab for high-volume operations
- New San Diego lab
- Mental Health lab renovation in Mason

**Reduce costs, enable scale**
- MyRisk
- Foresight
- Future assays on advanced sequencing platforms

**Develop new products**
- FirstGene
- Foresight panel expansion
- MRD
Labs of the future program advancements

Highlights
On-track executing against our strategy
• New facilities opened Q2/Q3 of 2023
• Shift to next-generation sequencing nearly complete
• Phase 1 next-generation automation expected in Q1 ’24

Benefits
• Streamlined workflows to deliver fast turnaround times
• Increased capability to innovate
• Backbone for advanced data capabilities
• Approximately $12M annual savings expected starting in 2025 from more efficient, centralized lab operations
Execution plan supported by significant investment

<table>
<thead>
<tr>
<th>NovaSeq Transitions</th>
<th>New Facility Construction</th>
<th>Shift Operations to New Facilities</th>
<th>Advanced Automation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prenatal products shift to advanced sequencing</td>
<td>Walter Gilbert Innovation Center construction</td>
<td>Transition Innovation operations to Walter Gilbert facility</td>
<td>Design and build first phases of automation</td>
</tr>
<tr>
<td>MyChoice products shift to advanced sequencing</td>
<td>Salt Lake City West Campus production lab construction</td>
<td>Transition Salt Lake City Research Park products to Salt Lake City West Campus</td>
<td>Early phase Prenatal lab automation</td>
</tr>
</tbody>
</table>

- 2022
  - Q1: Prenatal products shift to advanced sequencing
  - Q2: MyChoice products shift to advanced sequencing
  - Q3: Walter Gilbert Innovation Center construction
  - Q4: Salt Lake City West Campus production lab construction

- 2023
  - Q1: Transition Innovation operations to Walter Gilbert facility
  - Q2: Transition Salt Lake City Research Park products to Salt Lake City West Campus
  - Q3: Early phase Prenatal lab automation
  - Q4: Fully automate Prenatal labs

- 2024
- 2025

$80M* investment in modern labs
$12M annual savings expected starting in 2025

* >85% of investment is estimated to be capitalizable expense
Investments in structural change to improve the patient and provider experience, reduce costs, and improve reimbursement

Unified, skilled team
- One organization: payer markets, revenue cycle, authorization, customer service
- Rapid identification of key friction points with providers and patients

Frictionless automated workflows
- Unified Order Management
  - Redefining Customer Service team, processes and tools
  - Single system across all businesses for customer information, order details
  - Automated communication with patients and providers
- Revenue Cycle Platform
  - Automated engagement to improve billing accuracy, reducing no-pays

Order Management
A Leading Salesforce Order Management platform

Reimbursement
Automated revenue cycle management
Advanced analytics platform
Overall R&D strategy

Increase access—via innovation, product development, and evidence generation—to life-changing diagnostics that align with our core business goals
### Women's Health

<table>
<thead>
<tr>
<th>FirstGene™</th>
<th>Foresight™</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multiple prenatal screen</td>
<td>Expanded carrier screen</td>
</tr>
</tbody>
</table>

**What is It?**
- Integrated assay for NIPS + carrier screen + fetal recessive status + fetomaternal blood compatibility on a single blood draw on one person

**Key advantages**
- Faster turnaround time
- 3x lower cost of goods
- Established reimbursement

### Oncology

<table>
<thead>
<tr>
<th>Precise™ Tumor</th>
<th>Precise™ Liquid</th>
<th>Precise™ MRD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robust tumor profiling &amp; therapy selection</td>
<td>Robust tumor profiling &amp; therapy selection</td>
<td>Minimal residual disease monitoring</td>
</tr>
</tbody>
</table>

**What is It?**
- Pan-cancer comprehensive genomic profiling test using Illumina TruSight Oncology 500; may serve as first-line offering or as reflex if solid tumor is insufficient

**Key Advantages**
- Panel size ~2x size (500 genes) of lead competitor; uses both DNA/RNA; ease of use as part of Precise Oncology Solutions
- Established reimbursement path

**What is It?**
- Monitoring test based on whole genome sequencing to deeply interrogate tumor, detect recurrence earlier and help guide treatment decisions

**Key Advantages**
- Targets 10x variants
- Known path to reimbursement
## Sampling of key projects in flight

<table>
<thead>
<tr>
<th>Project</th>
<th>2023</th>
<th>2024</th>
<th>2025</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Q3</td>
<td>Q4</td>
<td>Q1</td>
</tr>
<tr>
<td>Foresight Expansion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Precise Liquid</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FirstGene™</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>VALIDATION &amp; RELOCATION</td>
<td>SOFT LAUNCH &amp; STUDY</td>
<td></td>
</tr>
<tr>
<td>Precise MRD</td>
<td>RUO</td>
<td>RELOCATION</td>
<td></td>
</tr>
<tr>
<td>Exome Platform</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **Commercialization Target**
- **RUO** (Research Use Only)
- **VALIDATION & RELOCATION**
- **SOFT LAUNCH & STUDY**
- **PHARMA AVAILABILITY**
Efficiency gains through integration on whole-exome platform
Platform upgrades to Foresight improve financials and enable product enhancement

- Lower COGS
- Lower OPEX
- Harmonized workflows across products
- Easier to increase content

Recently completed platform updates above unlock the following:

NEW sequencer + NEW chemistry + NEW hardware + NEW software
Foresight Universal Plus: Designed to meet anticipated medical-society guidelines

Today

176 Foresight genes

Q1 2024

274 Foresight genes

114 ACMG genes

ACOG genes

TBD
Transformative prenatal screen running multiple tests at once

Current PROBLEMS with prenatal genetic screening

Providers don’t have enough time to talk about genetics

Only 50% utilization of carrier screening

Only 30% of fathers get screened when mother is a carrier

Low gross margins on NIPS and ECS

New SOLUTION

FirstGene™
Multiple Prenatal Screen

- Easier for providers to administer integrated offering
- No need to screen the father
- Estimated 30-40% higher gross margins compared to Foresight or Prequel alone
Exemplary performance of FirstGene for fetal status nearing that of established prenatal screening

384-sample Verification Study conducted in preparation for Validation Study

<table>
<thead>
<tr>
<th></th>
<th>SENSITIVITY</th>
<th>SPECIFICITY</th>
<th>PPV</th>
<th>NPV</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Non-invasive</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prenatal Screening</td>
<td>100%</td>
<td>99.8%</td>
<td>93.5%</td>
<td>100%</td>
</tr>
<tr>
<td></td>
<td>(85.4%-100%)</td>
<td>(99.3%-100%)</td>
<td>(77.2%-98.9%)</td>
<td>(99.6%-100%)</td>
</tr>
<tr>
<td><strong>Carrier Screening</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recessive variants in pregnant person</td>
<td>99.9%</td>
<td>100%</td>
<td>100%</td>
<td>99.97%</td>
</tr>
<tr>
<td></td>
<td>(99.7%-99.9%)</td>
<td>(99.99%-100%)</td>
<td>(99.9%-100%)</td>
<td>(99.9%-99.9%)</td>
</tr>
<tr>
<td><strong>NEW!</strong> Fetal recessive status</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recessive variants in fetus</td>
<td>99.6%</td>
<td>98.8%</td>
<td>98.3%</td>
<td>99.7%</td>
</tr>
<tr>
<td></td>
<td>(98.8%-99.9%)</td>
<td>(97.8%-99.4%)</td>
<td>(97.0%-99.2%)</td>
<td>(99.1%-99.9%)</td>
</tr>
<tr>
<td><strong>NEW!</strong> Blood compatibility</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rhesus D Antigen*</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td></td>
<td>(2.5%-100%)</td>
<td>(2.5%-100%)</td>
<td>(2.5%-100%)</td>
<td>(2.5%-100%)</td>
</tr>
</tbody>
</table>

* Samples with confirmed Rhesus D (RhD) antigen status largely saved for Validation Study rather than use in Verification Study

FirstGene Validation Study started! (publication forthcoming)
Before getting to MRD... an important update to our comprehensive genomic profiling offering

Precise Tumor
Molecular Profile Test

Precise Liquid
Molecular Profile Test

- Both solid and liquid assays test >500 genes; solid test includes RNA analysis to detect fusions
- Precise Liquid can serve as stand-alone product for certain indications and reflex for cases where solid tumor sample is insufficient or low-quality
- Underlying panel utilized in >75 peer-reviewed manuscripts, including clinical validation studies
High-definition MRD: Differentiation built upon existing competencies

Tumor + normal sample prep and sequencing
Bioinformatic identification of somatic variants
cfDNA isolation and targeted sequencing
Detect presence or absence of tumor cfDNA

Comparable Myriad test

Competitor

MyChoice®CDx
Myriad HBD Companion Diagnostic Test

FirstGene™
In vitro Personalized Medicine

Somatic variant identification

Competitor

| Exome | Whole genome |

Number of sites interrogated in plasma sample

Competitor

| 16 sites | ≥500 sites |

Precise Minimal Residual Disease (MRD)

Higher sensitivity in more tumors (10x lower tumor fraction)

100x More of the genome explored

30x More sites

Earlier detection of recurrence
High-Definition MRD enables better treatment decisions

Precise Minimal Residual Disease (MRD)

16 sites
>500 sites
Excellent performance of high-definition MRD across tumor types

- ~100% sensitivity at 0.01% tumor fraction, the limit of detection of a 16-site assay
- Can handily achieve limit of detection that is 5x-10x lower than 16-site assay
- Requires 2x less tissue than exome-based MRD offerings
- Further improvements integrated since these experiments
Myriad and MD Anderson: Partnering to advance renal cell carcinoma care

Precise™ MRD
Minimal Residual Disease Monitoring

Top 10 cancer with ~82,000 newly diagnosed patients annually¹

High rates of recurrence among treated patients²

Using MRD analysis to stratify patients and adjust medical management for more tolerable treatment options

Study design
Testing 120 patients with recurrent RCC to assess clinical validity on Radiation + MRD

Why we’re excited
Test cohort is larger than other studies submitted to MolDx for reimbursement

¹. Data from American Cancer Society
Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer

Research will use Myriad’s high-definition MRD testing platform based on whole-genome sequencing

SALT LAKE CITY, Sept. 16, 2023 (BUSINESS WIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK) to study the use of minimal residual disease (MRD) testing in breast cancer. The research project will use Myriad’s MRD testing platform, a tumor-informed high-definition assay that uses whole-genome sequencing to achieve high sensitivity and specificity for circulating tumor DNA (ctDNA).

Study design
Two-phase study of 100 patients with metastatic breast cancer in neoadjuvant and adjuvant setting

Why we’re excited
Provides another avenue for Myriad to support women with breast cancer

“We anticipate the MRD test from Myriad will be more sensitive and specific than many other ctDNA offerings for monitoring the response and, therefore, may more accurately identify the patients who will or will not benefit from certain therapies. Importantly, some of these patients may go undetected on a less-sensitive MRD test.”

Dr. Pedram Razavi,
Director of Liquid Biopsy & Genomics
Memorial Sloan Kettering Cancer Center
High-definition MRD: Key milestones

2023

- Launch Research-Use-Only (RUO) test

  Partner on retrospective clinical validation
  Work with leading cancer centers eager to use HD-MRD

  Begin prospective clinical validity study
  Three institutions onboarded; patient enrollment underway

2024

- Offer HD-MRD for biopharma partners

  Publish clinical validity studies
  Retrospective longitudinal cohorts; one per indication

  Submit for reimbursement to CMS
  Show non-inferiority to currently covered tumor-informed tests

  Commence clinical-utility study
  Focus on provider utilization and patient outcomes

  Scale laboratory operations
  Low-touch, high-capacity, and high-quality with low COGS

2025

- Launch Lab Developed Test (LDT)

  Continue scaling laboratory operations
  Low-touch, high-capacity, and high-quality with low COGS

Precise Minimal Residual Disease (MRD)
Katie Johansen Taber Ph.D.
VP, CLINICAL PRODUCT RESEARCH & PARTNERSHIPS

Closer look at clinical programs and real-world evidence
# Establishing the evidence: A robust study and publication pipeline

<table>
<thead>
<tr>
<th>STUDIES AND PUBLICATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active studies</td>
</tr>
<tr>
<td>Journal submissions 2023-2024</td>
</tr>
<tr>
<td>Conference presentations 2023 YTD</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FirstGene</strong>&lt;sup&gt;™&lt;/sup&gt; Multiple Prenatal Screen</td>
<td>Analytical validation study expected to be submitted by EOY ‘23</td>
</tr>
<tr>
<td><strong>MyRisk</strong>&lt;sup&gt;®&lt;/sup&gt; Hereditary Cancer Test</td>
<td>MyRisk with RiskScore ancestry-specific performance presented as podium at ASCO ‘23</td>
</tr>
<tr>
<td><strong>Prolaris</strong>&lt;sup&gt;®&lt;/sup&gt; Prostate Cancer Prognostic Test</td>
<td>Manuscript demonstrating value of Absolute Risk Reduction ready for submission</td>
</tr>
<tr>
<td><strong>GeneSight</strong>&lt;sup&gt;®&lt;/sup&gt; Mental Health Medication Test</td>
<td>Meta-analysis showed that access to GeneSight improved Major Depressive Disorder (MDD) response and remission rates</td>
</tr>
</tbody>
</table>

Olopade et al, ASCO 2023  
Dyer et al., Psych Congress 2023
Real-world analysis of GeneSight shows decrease in hospitalizations

Study background

Compare deidentified healthcare claims among >20,000 patients receiving GeneSight

Assess changes in healthcare utilization before and after GeneSight

Phase I: Preliminary results

In the 180 days after GeneSight

- **DECREASED** total hospitalizations by more than 25%
- **DECREASED** psychiatric hospitalizations by more than 35%

No change in non-psychiatric hospitalizations

Additional data and detail to be included in upcoming manuscript

Next phase of study will include additional control groups and economic analyses

Manuscript in preparation
This study used data from the Optum Labs Data Warehouse, composed of de-identified administrative claims data for both commercially insured and Medicare Advantage enrollees. The claims data were linked on a de-identified basis with PGx test results.
Amplify drives 100% positive predictive value for 22q11.2 microdeletion

Prequel’s positive predictive value for 22q11.2 microdeletion is **100%**, nearly double that of the leading competitor (52.6%).

<table>
<thead>
<tr>
<th></th>
<th>Prequel with Amplify*</th>
<th>Competitor offering (Dar et al, 2022)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total cohort</td>
<td>379,428</td>
<td>18,289</td>
</tr>
<tr>
<td>Average fetal fraction in screen-positive cases</td>
<td>22.7%</td>
<td>9.8%</td>
</tr>
<tr>
<td>Positive predictive value</td>
<td>100% (CI 84.6%-100%)</td>
<td>52.6% (CI 28.9%-75.6%)</td>
</tr>
</tbody>
</table>

“NIPS for 22q11.2 Deletion Syndrome Should Be Offered to All Patients”

American College of Medical Genetics and Genomics (Dungan et al, 2022)
Building the required clinical evidence for Precise MRD

<table>
<thead>
<tr>
<th>Indication</th>
<th>Study Types</th>
<th>Total Patients</th>
<th>Statuses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast (x4)</td>
<td>●●●</td>
<td>910</td>
<td>Enrolling, contracted, proposal</td>
</tr>
<tr>
<td>Renal (x3)</td>
<td>●●</td>
<td>370</td>
<td>Running samples, contracting</td>
</tr>
<tr>
<td>Ovarian (x3)</td>
<td>●●</td>
<td>720</td>
<td>Proposal</td>
</tr>
<tr>
<td>Multicancer</td>
<td>●</td>
<td>1000</td>
<td>Contracting</td>
</tr>
<tr>
<td>Other (x4)</td>
<td>●●</td>
<td>&gt;200</td>
<td>Contracting, Proposal</td>
</tr>
</tbody>
</table>

- 3,200 patients
- >20,000 timepoints
- 6+ indications

Myriad Prospective

Investigator-Initiated Prospective

Retrospective Collaboration

Prospective Interventional
MRD in breast cancer: Aggressive evidence generation

MONITOR-Breast

Study Design
Multi-site, Prospective, Observational

Target enrollment
650 patients in 3 groups:
HR+/HER2-, HER2+, Triple-negative

Sample collection at diagnosis, neoadjuvant treatment, surgery,
post-surgery, adjuvant treatment, and after treatment

Status
3 sites actively enrolling, 7-10 additional sites in contracting
Bryan Riggsbee

CHIEF FINANCIAL OFFICER

Delivering shareholder value
Momentum reflected in diversified volume growth

**Total test volume**

- **+16% LTM² Growth**

**LTM² volume growth (YOY) across breadth of product offerings:**
- Genesight: +27%
- Hereditary cancer: +16%
- Prolaris: +15%
- Prenatal¹: +6%

**Volume growth driven by:**
- Commercial execution across current provider base; winning new business
- Improving provider perceptions
- Operational execution (e.g., lower turnaround times)
- Shifts in competitive landscape across select markets

---

**Figures in thousands**

1. Excluding contribution from SneakPeek Early Gender DNA test and divested businesses
2. Last twelve months as of June 30, 2023
Significant opportunity from revenue cycle management, payer engagement, and increased advocacy

Growing awareness and understanding of the value of genetic testing

- April 2022 OIG report on denials of prior authorization requests by Medicare Advantage plans thus hindering access to medically necessary care
- Increasing number of state biomarker laws enacted; engage payers and laboratory coalitions to ensure medical policies align

Expanding payer coverage

- Medical association guideline expansion for Foresight® carrier screen (awaiting)
- A number of Medicaid programs have priced, and begun paying for GeneSight® mental health medication test as of Q2 ’23

Revenue cycle management capabilities

High ROI automation and analytics:
- Over $40 million improvement in cash collections since ’21
- +55% increase in prior authorization team productivity*

* Time period reflects CY 2021 - CY 2022
Addressing the challenge of non-payment

Zero Pays: Result from claims that were denied by insurance and patient did not provide any payment for tests we’ve already processed through the laboratory.

Claim Denials: most common reasons fall into three categories

Harder to solve

Medical Necessity / Experimental
• Product not covered for anyone
• Product is covered, but patient does not meet medical policy

Authorization
• Failed to obtain prior authorization
• Provider failed to obtain authorization
• Authorization denied

Documentation / Medical Records
• Missing records from provider
• Provider records did not sufficiently support medical necessity
Focused efforts to drive near-term improvement in no-pay rate

**Focus on the ground game**
Payor compliance to current guidelines

- State biomarker laws leading to new coverage opportunities
- Bolster “go-to-market” messaging and targeting for GeneSight

**Process improvements**
Revenue cycle operations

- Accelerate large-scale EMR integrations to mitigate issues with missing data
- Deploy Unified Order Management to reduce friction for Billing
- AI-enhanced insights to rapidly surface and resolve emerging payment hot spots
- Optimize customer journey for Direct Pay for those who don’t meet guidelines or don’t have coverage

**Augment the pre-auth team**
Hire and add robotic processing (RPA)

- Invest in added team members to keep up with double-digit growth and associated increased authorizations
- Add RPA to off-load repetitive tasks

Estimated +$40M revenue opportunity in 2024 - 2026
Accelerating growth expected through prudent investment strategy

Potential path to $1 billion+ in 2026

Total revenue¹,³

<table>
<thead>
<tr>
<th>Year</th>
<th>Revenue</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>$400</td>
</tr>
<tr>
<td>2022</td>
<td>$500</td>
</tr>
<tr>
<td>2023E</td>
<td>$600</td>
</tr>
<tr>
<td>2026</td>
<td>$1,000</td>
</tr>
</tbody>
</table>

¹. Excluding contribution from SneakPeek Early Gender DNA test and divested businesses
². Last twelve months as of June 30, 2023. Excluding contribution from SneakPeek Early Gender DNA test, divested business, and out-of-period adjustments.
³. 2023 revenue reflects the mid-point of current revenue guidance range of between $730M - $750M

10%+ CAGR (24’-26)

LTM² revenue growth of 10% driven broadly across product offerings:
- Prolaris: +20%
- Genesight: +18%
- Prenatal¹: +13%
- Hereditary cancer: +6%

Expect 10%+ total revenue growth across portfolio, including HCT growing mid-single digits

Expect annual revenue growth to be driven by current core portfolio with potential upside beginning in ’25 driven by the commercial launch of FirstGene and Precise MRD
Opportunity for adjusted gross margin expansion through 2026

Potential gross margin expansion

Gross margin¹,³

<table>
<thead>
<tr>
<th>Year</th>
<th>Total Revenue</th>
<th>Gross Margin</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>$400</td>
<td>$68 - 70%</td>
</tr>
<tr>
<td>2022</td>
<td>$500</td>
<td></td>
</tr>
<tr>
<td>2023E</td>
<td>$600</td>
<td></td>
</tr>
<tr>
<td>2026 Target</td>
<td>$900</td>
<td>70% + 100-200 Basis pts</td>
</tr>
</tbody>
</table>

Current gross margins at upper end of specialty lab industry range

Gross margins through 2026 are expected to benefit from:

- Accelerating volume growth
- Product mix
- Lab transition to advanced automation
- Revenue Cycle Management progress

Cost of Goods Sold (COGS) consists of approx. 30% headcount, 40% supplies, and 30% overhead. Opportunity for fixed cost leverage and cost savings in materials

¹. Excluding contribution from divested businesses
². 2023 revenue reflects the mid-point of current revenue guidance range of between $730M - $750M
³. 2026 non-GAAP gross margin begins with the comparable GAAP financial measure and excludes the estimated impact of stock-based compensation expense of $1 million, and non-cash amortization associated with acquisitions of $1 million.
SG&A operating leverage through 2026

Current salesforce of 650+ FTEs is appropriately sized per business unit

Sales headcount, by business unit (% of total salesforce FTEs)

<table>
<thead>
<tr>
<th>Business Unit</th>
<th>Headcount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Women’s Health</td>
<td>40%</td>
</tr>
<tr>
<td>Oncology</td>
<td>34%</td>
</tr>
<tr>
<td>Pharmacogenomics</td>
<td>26%</td>
</tr>
</tbody>
</table>

SG&A targets

~1000 basis points lower in 2026

Targeting 2026 SG&A to be ~1000 basis points lower than 2023 SG&A as a percentage of revenue.

+5-6% annual growth

Disciplined spend in SG&A; target SG&A expense growth of approx. 5% annually, with modest headcount additions.
Potential expansion of adjusted operating income driven by elevated revenue growth and focus on cost structure

Target at least $100 million in adjusted operating income in 2026, or 10% of total revenue

Adjusted operating income expansion through 2026 driven by generating:

- 10%+ annual revenue growth due to strong test volume growth
- Expanding gross margins
- 5-6% annual adjusted opex growth

*2026 adjusted operating income target begins with the comparable GAAP financial measure and excludes the estimated impact of stock-based compensation expense of approximately $46.0 million, non-cash amortization associated with acquisitions of approximately $43.0 million and special items such as costs related to transformation initiatives of approximately $4.0 million.
### Reaffirm 2023 revenue and non-GAAP financial guidance

<table>
<thead>
<tr>
<th>Total revenue</th>
<th>2023 financial guidance</th>
<th>2023 comments</th>
<th>2024 - 2026 commentary</th>
<th>Additional comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>$730 - $750</td>
<td>$730 - $750</td>
<td>2023 annual growth between 8% - 11% over 2022.</td>
<td>10%+ CAGR</td>
<td>Target total revenue of over $1 billion in 2026. This revenue target includes modest contribution from planned new products and no contribution from future M&amp;A.</td>
</tr>
<tr>
<td>Gross margin %</td>
<td>68% - 70%</td>
<td>GM expected to fluctuate in any quarter given seasonality.</td>
<td>70%+</td>
<td>GM expected to fluctuate in any quarter given product mix, pricing trends and seasonality.</td>
</tr>
<tr>
<td>Adjusted operating expenses*</td>
<td>$535 - $555</td>
<td></td>
<td>5-6% CAGR</td>
<td>Balance ongoing investment in R&amp;D with ongoing cost controls in SG&amp;A.</td>
</tr>
<tr>
<td>Adjusted EPS*</td>
<td>$(0.36) - $(0.24)</td>
<td>Adjusted EPS is expected to reach positive adjusted profitability and adjusted operating cash flow in Q4 ’23.</td>
<td>Positive adjusted operating income and adjusted cash flow</td>
<td>Target adjusted operating income of approximately $100 million in 2026**, or 10% of total revenue in 2026. Adjusted operating cash flow is expected to be in-line with adjusted operating income trend.</td>
</tr>
</tbody>
</table>

** Assumes currency rates as of September 19, 2023

---

** Fiscal year 2023 non-GAAP guidance begins with the comparable GAAP financial measure and excludes the estimated impact of stock-based compensation expense of approximately $40 million, non-cash amortization associated with acquisitions of approximately $43 million and special items such as costs related to transformation initiatives of approximately $24 million, legal settlement costs of approximately $80 million, and tax adjustments of approximately $8 million.

** 2026 adjusted operating income target begins with the comparable GAAP financial measure and excludes the estimated impact of stock-based compensation expense of approximately $46.0 million, non-cash amortization associated with acquisitions of approximately $43.0 million and special items such as costs related to transformation initiatives of approximately $4.0 million.
Capital structure and positive adjusted cash flow expected in 2024 and beyond

- Positive adjusted operating cash flow in Q4 '23; through 2026, adjusted operating cash flow** is expected to trend in-line with adjusted operating income

- CapEx spend in 2024 and beyond is expected to be approx $5 - $6 million a quarter

- $90 million asset-based credit facility: Plan to expand to $115M which is expected to increase availability by $10 million*

- Target $111 million in total available cash and cash equivalents and availability under credit facility at year end 2023

* The Company plans to increase the size of the ABL facility by $25 million to $115 million by the end of 2023, which is expected to increase availability under the ABL facility from $23.5 million to $33.5 million.

** Adjusted operating cash flow is a Non-GAAP measure. See the Appendix to this presentation for the definition.
Closing thoughts
Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Six Months ended June 30, 2023 and 2022

(unaudited data in millions, except per share amounts)

<table>
<thead>
<tr>
<th></th>
<th>Three months ended June 30,</th>
<th></th>
<th>Six months ended June 30,</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2023</td>
<td>2022</td>
<td>2023</td>
<td>2022</td>
</tr>
<tr>
<td>Adjusted Gross Margin</td>
<td>$ 125.7</td>
<td>$ 129.6</td>
<td>$ 247.7</td>
<td>$ 246.5</td>
</tr>
<tr>
<td>GAAP Gross Profit</td>
<td>0.4</td>
<td>0.2</td>
<td>0.7</td>
<td>0.5</td>
</tr>
<tr>
<td>Equity compensation</td>
<td>0.3</td>
<td>–</td>
<td>0.6</td>
<td>–</td>
</tr>
<tr>
<td>Acquisition - amortization of intangible assets</td>
<td>0.2</td>
<td>–</td>
<td>0.2</td>
<td>–</td>
</tr>
<tr>
<td>Transformation initiatives</td>
<td>69.0%</td>
<td>72.4%</td>
<td>68.3%</td>
<td>71.8%</td>
</tr>
</tbody>
</table>

(1) Consists of total revenues less cost of testing from the Condensed Consolidated Statements of Operations.

<table>
<thead>
<tr>
<th></th>
<th>Three months ended June 30,</th>
<th></th>
<th>Six months ended June 30,</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2023</td>
<td>2022</td>
<td>2023</td>
<td>2022</td>
</tr>
<tr>
<td>Adjusted Operating Expenses</td>
<td>$ 239.4</td>
<td>$ 147.4</td>
<td>$ 413.6</td>
<td>$ 289.9</td>
</tr>
<tr>
<td>GAAP Operating Expenses</td>
<td>(10.3)</td>
<td>(10.1)</td>
<td>(20.6)</td>
<td>(20.3)</td>
</tr>
<tr>
<td>Acquisition - amortization of intangible assets</td>
<td>(10.8)</td>
<td>(9.9)</td>
<td>(17.9)</td>
<td>(19.7)</td>
</tr>
<tr>
<td>Goodwill and long-lived asset impairment charges</td>
<td>(6.2)</td>
<td>(3.7)</td>
<td>(17.8)</td>
<td>(7.7)</td>
</tr>
<tr>
<td>Transformation initiatives</td>
<td>(77.9)</td>
<td>1.6</td>
<td>(78.2)</td>
<td>12.9</td>
</tr>
<tr>
<td>Legal charges, net of insurance reimbursement</td>
<td>(0.8)</td>
<td>–</td>
<td>(1.2)</td>
<td>0.9</td>
</tr>
<tr>
<td>Other adjustments</td>
<td>133.4</td>
<td>125.3</td>
<td>277.9</td>
<td>245.3</td>
</tr>
</tbody>
</table>

(1) Consists of research and development expense, selling, general, and administrative expense, and goodwill and long-lived asset impairment charges from the Condensed Consolidated Statements of Operations.
Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Six Months ended June 30, 2023 and 2022

(unaudited data in millions, except per share amounts)

<table>
<thead>
<tr>
<th></th>
<th>Three months ended</th>
<th></th>
<th>Six months ended</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>June 30, 2023</td>
<td>2023</td>
<td>June 30, 2023</td>
<td>2022</td>
</tr>
<tr>
<td>Adjusted Operating Income (Loss)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAAP Operating Loss</td>
<td>$(113.7)</td>
<td>$(17.8)</td>
<td>$(165.9)</td>
<td>$(43.4)</td>
</tr>
<tr>
<td>Acquisition - amortization of intangible assets</td>
<td>10.7</td>
<td>10.1</td>
<td>21.3</td>
<td>20.3</td>
</tr>
<tr>
<td>Goodwill and long-lived asset impairment charges</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>10.7</td>
</tr>
<tr>
<td>Equity compensation</td>
<td>11.1</td>
<td>10.1</td>
<td>18.5</td>
<td>20.2</td>
</tr>
<tr>
<td>Transformation initiatives</td>
<td>6.4</td>
<td>3.7</td>
<td>18.0</td>
<td>7.7</td>
</tr>
<tr>
<td>Legal charges, net of insurance reimbursement</td>
<td>77.9</td>
<td>(1.6)</td>
<td>78.2</td>
<td>(12.9)</td>
</tr>
<tr>
<td>Other adjustments</td>
<td>0.8</td>
<td>—</td>
<td>1.2</td>
<td>(0.9)</td>
</tr>
<tr>
<td>Adjusted Operating Income (Loss)</td>
<td>$(6.8)</td>
<td>4.5</td>
<td>$(28.7)</td>
<td>1.7</td>
</tr>
</tbody>
</table>

| Adjusted Net Loss (1)         | Three months ended |       | Six months ended |       |
|                               | June 30, 2023      | 2023  | June 30, 2023    | 2022  |
| GAAP Net Loss                 | $(16.1)            | $(14.1) | $(170.8)         | $(34.6) |
| Acquisition - amortization of intangible assets | 10.7 | 10.1 | 21.3 | 20.3 |
| Goodwill and long-lived asset impairment charges | — | — | — | 10.7 |
| Equity compensation           | 11.1               | 10.1  | 18.5             | 20.2  |
| Transformation initiatives    | 6.4                | 3.7   | 18.0             | 7.7   |
| Legal charges, net of insurance reimbursement | 77.9 | (1.6) | 78.2             | (12.9) |
| Other adjustments             | 0.8                | —     | 1.2              | (0.9)  |
| Tax adjustments               | 2.8                | (4.7) | 9.8              | (9.8)  |
| Adjusted Net Income (Loss)    | $(6.4)             | 3.5   | $(23.8)          | 0.7   |

Weighted average shares outstanding:

<table>
<thead>
<tr>
<th></th>
<th>Basic</th>
<th>Diluted</th>
<th>Adjusted Earnings Per Share</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic</td>
<td>81.7</td>
<td>80.4</td>
<td>$(0.08)</td>
</tr>
<tr>
<td>Diluted</td>
<td>81.7</td>
<td>81.0</td>
<td>$(0.04)</td>
</tr>
</tbody>
</table>

(1) To determine Adjusted Earnings Per Share, or adjusted EPS.
### Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Six Months ended June 30, 2023 and 2022

*(unaudited data in millions, except per share amounts)*

<table>
<thead>
<tr>
<th></th>
<th>Three months ended June 30,</th>
<th>Six months ended June 30,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2023</td>
<td>2022</td>
</tr>
<tr>
<td>Cash flow from operations</td>
<td>$ (0.9)</td>
<td>$ (49.7)</td>
</tr>
<tr>
<td>Transformation initiatives</td>
<td>6.4</td>
<td>3.7</td>
</tr>
<tr>
<td>Legal charges, net of insurance reimbursement</td>
<td>0.4</td>
<td>47.0</td>
</tr>
<tr>
<td>Other adjustments</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Adjusted operating cash flow</td>
<td>$ 5.9</td>
<td>$ 1.0</td>
</tr>
<tr>
<td>Capital expenditures</td>
<td>(18.8)</td>
<td>(6.7)</td>
</tr>
<tr>
<td>Adjusted free cash flow(^1)</td>
<td>$ (12.9)</td>
<td>$ (5.7)</td>
</tr>
</tbody>
</table>

|                      | 2023                        | 2022                      |
|                      | $ (34.1)                    | $ (96.2)                  |
|                      | $ 12.3                      | $ 7.7                     |
|                      | 2.2                         | 49.9                      |
|                      | 0.4                         | —                         |
|                      | $ (19.2)                    | $ (38.6)                  |
|                      | $ (42.3)                    | $ (13.0)                  |
|                      | $ (61.5)                    | $ (51.6)                  |

\(^1\) The company has revised its Adjusted Free Cash Flow metric in the quarter ended June 30, 2022 to exclude the tax impact, if any, associated with non-GAAP adjustments.
Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Six Months ended June 30, 2023 and 2022

(unaudited data in millions, except per share amounts)

Following is a description of the adjustments made to GAAP financial measures:

- Acquisition – amortization of intangible assets – represents recurring amortization charges resulting from the acquisition of intangible assets.
- Goodwill and long-lived asset impairment charges – impairment charges on long-lived assets and goodwill.
- Equity compensation – non-cash equity-based compensation provided to Myriad Genetics employees and directors.
- Transformation initiatives – transitory costs such as consulting and professional fees related to transformation initiatives, additional rent as a result of the build-out of the company’s new laboratories in Salt Lake City, Utah and in South San Francisco, California, while maintaining its current laboratories in those locations, re-location costs of equipment to new laboratories, severance costs, and accelerated depreciation in connection with the company’s decision to cease the use of its former corporate headquarters in Salt Lake City, Utah. With respect to the adjusted free cash flow reconciliation, the cash flow effect of transformation initiatives excludes non-cash items such as accelerated depreciation.
- Legal charges, net of insurance reimbursement – one-time legal expenses, net of insurance reimbursement. With respect to the adjusted free cash flow reconciliation, the cash flow effect includes cash paid for settlements in the related period.
- Other adjustments – other one-time non-recurring expenses including consulting and professional fees related to prior year acquisitions, changes in the fair value of contingent consideration related to acquisitions from prior years and reclassifications of cumulative translation adjustments to income upon liquidation of an investment in a foreign entity.
- Tax adjustments – tax expense/(benefit) due to non-GAAP adjustments, differences between stock compensation recorded for book purposes as compared to the allowable tax deductions, and valuation allowance recognized against federal and state deferred tax assets in the United States. A valuation allowance of $37.2 million was not recognized for non-GAAP purposes given the company’s historical and forecasted positive earnings performance.

1 Change of estimates may include both positive and negative adjustments primarily driven by changes in the estimated transaction price due to contractual adjustments, actual cash collections, and obtaining updated information from payors and patients that was unknown at the time revenue was recognized.